文献速递MDS 与骨髓增殖性肿瘤白血病

基于DREAM的简易甲基化检测用于幼年型粒单核细胞白血病风险分层

Simple and robust methylation test for risk stratification of patients with juvenile myelomonocytic leukemia.
PubMed 文献 · Blood Adv · 2021-01-01

该研究利用基于下一代测序的DREAM甲基化分析方法,对137例幼年型粒单核细胞白血病(JMML)患者进行分析。在可比较的98例中,90例高甲基化(HM)和低甲基化(LM)病例与DREAM聚类结果100%一致;中间甲基化(IM)组8例中4例归为HM_DREAM、4例归为LM_DREAM。基于支持向量机(SVM)的机器学习分类器将验证队列(n=38)分为HM_SVM(n=18)和LM_SVM(n=20),HM_SVM组5年总生存率显著低于LM_SVM组。研究结论为开发了一种稳健的DREAM甲基化检测,可纳入诊断以生成甲基化分类,便于未来临床试验中实施风险 adapted 治疗。

要点

  • DREAM甲基化检测可将JMML患者分为HM和LM两组,与国际共识分类高度一致。
  • 基于SVM的分类器在验证队列中成功区分HM_SVM和LM_SVM,HM_SVM组5年总生存率显著更差。
  • 该检测简单稳健,可纳入诊断流程,支持风险 adapted 治疗。

核心结论

  • 开发了一种基于DREAM的稳健甲基化检测,可用于JMML患者的风险分层。

研究设计与样本

  • 研究分析了137例JMML患者,使用基于下一代测序的DREAM方法进行甲基化分析。
  • 发现队列(n=99)通过无监督共识聚类识别HM_DREAM(n=35)和LM_DREAM(n=64)亚组。
  • 验证队列(n=38)使用支持向量机(SVM)构建机器学习分类器,分为HM_SVM(n=18)和LM_SVM(n=20)。

主要发现

  • 在98例可比较病例中,90例HM(n=30)和LM(n=60)病例与DREAM聚类结果100%一致。
  • 剩余8例IM组病例中,4例归为HM_DREAM,4例归为LM_DREAM。
  • HM_SVM组患者的5年总生存率显著低于LM_SVM组患者。

关键数值与推荐

  • HM_DREAM组35例,LM_DREAM组64例(发现队列n=99)。
  • HM_SVM组18例,LM_SVM组20例(验证队列n=38)。
  • 90例HM(n=30)和LM(n=60)病例与DREAM聚类结果100%一致。

临床怎么用

  • 该简单直接的检测可 easily 纳入诊断,生成甲基化分类,帮助患者在未来临床试验中接受风险 adapted 治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Juvenile myelomonocytic leukemia (JMML) is a rare myelodysplastic/myeloproliferative neoplasm that develops during infancy and early childhood. The array-based international consensus definition of DNA methylation has recently classified patients with JMML into the following 3 groups: high (HM), intermediate (IM), and low methylation (LM). To develop a simple and robust methylation clinical test, 137 patients with JMML were analyzed using the Digital Restriction Enzyme Analysis of Methylation (DREAM), which is a next-generation sequencing-based methylation analysis. Unsupervised consensus clustering of the discovery cohort (n = 99) using DREAM data identified HM (HM_DREAM; n = 35) and LM subgroups (LM_DREAM; n = 64). Of the 98 cases that could be compared with the international consensus classification, 90 HM (n = 30) and LM (n = 60) cases had 100% concordance with DREAM clustering results. Of the remaining 8 cases comprising the IM group, 4 were classified as belonging to the HM_DREAM group and 4 to the LM_DREAM group. A machine-learning classifier was successfully constructed using a support vector machine (SVM), which divided the validation cohort (n = 38) into HM (HM_SVM, n = 18) and LM (LM_SVM; n = 20) groups. Patients with the HM_SVM profile had a significantly poorer 5-year overall survival rate than those with the LM_SVM profile. In conclusion, we developed a robust methylation test using DREAM for patients with JMML. This simple and straightforward test can be easily incorporated into diagnosis to generate a methylation classification for patients so they can receive risk-adapted treatment in the context of future clinical trials.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kitazawa H, Okuno Y, Muramatsu H, et al. Simple and robust methylation test for risk stratification of patients with juvenile myelomonocytic leukemia. Blood Adv. 2021. PMID: 34580726. doi:10.1182/bloodadvances.2021005080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。